Atreca

Atreca is a biotechnology and biopharmaceutical company that is developing novel therapeutics that is based on a deep understanding of the human immune response. Atreca develops technology to identify set of antibodies that are produced during an immune response, without the knowledge of an antigen.

Its product, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discoveryplatform.

It is a company that focuses on the immune responses of patients in therapeutic areas where such responses are the key phenomenon driving clinical outcomes, by enabling to discover and develop novel immunotherapies, including those in its lead programs in oncology.

The proprietary Atreca Discovery Platform has been validated repeatedly through partnerships with major pharmaceutical companies, non-profit foundations, academic institutions, and governmental entities. Its experienced leadership is supported by recognized technical advisors and leading investors that are dedicated to building a company with a worldwide and lasting impact on human health.